Kangabio Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$15M
- Investors
-
4
Kangabio General Information
Description
Researcher and developer of drugs intend to serve the pharmaceutical industry. The company is mainly focused on the research and development of clinical drug discovery and includes innovative prodrug molecules for immune agonists and multispecific antibodies, providing clients with potential treatment with less toxicity.
Contact Information
Website
www.kangabio.comCorporate Office
- Building 8
- Number 151 Libing Road, Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- Building 8
- Number 151 Libing Road, Pudong New Area
- Shanghai, 201203
- China
Kangabio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Dec-2025 | $15M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 26-Jun-2022 | Completed | Generating Revenue |
Kangabio Patents
Kangabio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026201125-A1 | T cell engager antibody | Pending | 28-Mar-2025 | ||
| JP-2026514090-A | Multifunctional molecule containing shielding interleukin 12 and method of use | Pending | 12-Apr-2023 | ||
| AU-2024251934-A1 | Multifunctional molecules comprising masked interleukin 12 and methods of use | Pending | 12-Apr-2023 | ||
| EP-4695282-A1 | Multifunctional molecules comprising masked interleukin 12 and methods of use | Pending | 12-Apr-2023 | ||
| WO-2024212827-A1 | Multifunctional molecules comprising masked interleukin 12 and methods of use | Inactive | 12-Apr-2023 | C07K14/5434 |
Kangabio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BOHE Angel Fund | Venture Capital | Minority | ||
| Daoyuan Capital | Venture Capital | Minority | ||
| Taikun Fund | Venture Capital | Minority | ||
| Teda VC | Venture Capital | Minority |
Kangabio FAQs
-
When was Kangabio founded?
Kangabio was founded in 2021.
-
Where is Kangabio headquartered?
Kangabio is headquartered in Shanghai, China.
-
What industry is Kangabio in?
Kangabio’s primary industry is Drug Discovery.
-
Is Kangabio a private or public company?
Kangabio is a Private company.
-
What is Kangabio’s current revenue?
The current revenue for Kangabio is .
-
How much funding has Kangabio raised over time?
Kangabio has raised $29.9M.
-
Who are Kangabio’s investors?
BOHE Angel Fund, Daoyuan Capital, Taikun Fund, and Teda VC have invested in Kangabio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process